Ana Castro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1209685/publications.pdf

Version: 2024-02-01

75 papers	3,184 citations	186209 28 h-index	155592 55 g-index
87 all docs	87 docs citations	87 times ranked	3836 citing authors

#	Article	IF	Citations
1	First Non-ATP Competitive Glycogen Synthase Kinase 3 Î² (GSK-3Î²) Inhibitors:Â Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2002, 45, 1292-1299.	2.9	421
2	Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Medicinal Research Reviews, 2002, 22, 373-384.	5.0	302
3	Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors. Current Pharmaceutical Design, 2006, 12, 4377-4387.	0.9	187
4	Donepezilâ€“tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorganic and Medicinal Chemistry, 2005, 13, 6588-6597.	1.4	145
5	Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2001, 1, 267-272.	1.1	134
6	Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles. Bioorganic and Medicinal Chemistry, 2006, 14, 1644-1652.	1.4	128
7	Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structureâ€“Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimerâ€™s Disease. Journal of Natural Products, 2007, 70, 1397-1405.	1.5	123
8	The use of leucocyte and plateletâ€rich fibrin in socket management and ridge preservation: a splitâ€mouth, randomized, controlled clinical trial. Journal of Clinical Periodontology, 2016, 43, 990-999.	2.3	122
9	SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives:â€‰ Exploration of Structural Requirements for Glycogen Synthase Kinase 3 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 7103-7112.	2.9	114
10	Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors. Medicinal Research Reviews, 2005, 25, 229-244.	5.0	111
11	Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2006, 15, 1-12.	1.9	97
12	N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2000, 35, 913-922.	2.6	78
13	5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 2012, 55, 1645-1661.	2.9	76
14	Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides:â€‰ First Phosphodiesterase 7 Inhibitors. Journal of Medicinal Chemistry, 2000, 43, 683-689.	2.9	74
15	Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 505-510.	1.0	58
16	Non-ATP competitive glycogen synthase kinase 3Î² (GSK-3Î²) inhibitors: Study of structural requirements for thiadiazolidinone derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 495-510.	1.4	57
17	Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?. Expert Opinion on Therapeutic Patents, 2002, 12, 1527-1536.	2.4	49
18	CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. European Journal of Medicinal Chemistry, 2001, 36, 333-338.	2.6	48

#	Article	IF	Citations
19	Heteroarylnitrones as Drugs for Neurodegenerative Diseases: Synthesis, Neuroprotective Properties, and Free Radical Scavenger Properties. Journal of Medicinal Chemistry, 2008, 51, 6150-6159.	2.9	48
20	Design and synthesis of N-benzylpiperidineâ€“purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. Bioorganic and Medicinal Chemistry, 2005, 13, 6795-6802.	1.4	46
21	Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: Synthesis, biological evaluation, and structureâ€“activity relationships. Bioorganic and Medicinal Chemistry, 2007, 15, 2768-2781.	1.4	43
22	Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimerâ€™s disease and other neurodegenerative disorders. Expert Opinion on Therapeutic Patents, 2000, 10, 1519-1527.	2.4	39
23	Synthesis and Potential Muscarinic Receptor Binding and Antioxidant Properties of 3-(Thiadiazolyl)pyridine 1-Oxide Compounds. Archiv Der Pharmazie, 1999, 332, 191-194.	2.1	35
24	In VivoAnti-Chagas Vinylthio-, Vinylsulfinyl-, and Vinylsulfonylbenzofuroxan Derivativesâ€¡. Journal of Medicinal Chemistry, 2007, 50, 6004-6015.	2.9	35
25	CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood-Brain Barrier Permeability of Structurally Diverse Drugs. QSAR and Combinatorial Science, 2004, 23, 89-98.	1.5	34
26	Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments. , 0, , 125-154.		34
27	Non-Cholinergic Pharmacotherapy Approaches to the Future Treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2002, 2, 37-50.	1.1	33
28	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. European Journal of Medicinal Chemistry, 2008, 43, 1349-1359.	2.6	33
29	Marine compounds for the therapeutic treatment of neurological disorders. Expert Opinion on Therapeutic Patents, 2005, 15, 1377-1386.	2.4	30
30	Benzothiadiazine Dioxide Dibenzyl Derivatives as Potent Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Comparative Molecular Field Analysis. Journal of Medicinal Chemistry, 2000, 43, 3218-3225.	2.9	27
31	Nonnucleoside Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Antiviral Evaluation of (Chlorophenylmethyl)benzothiadiazine Dioxide Derivatives. Journal of Medicinal Chemistry, 2000, 43, 3267-3273.	2.9	27
32	Recent strategies in the development of new human cytomegalovirus inhibitors. Medicinal Research Reviews, 2001, 21, 227-244.	5.0	27
33	Novel Potential Agents for Human Cytomegalovirus Infection:â€‰ Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides. Journal of Medicinal Chemistry, 1999, 42, 1145-1150.	2.9	26
34	New heteroaryl nitrones with spin trap properties: Identification of a 4-furoxanyl derivative with excellent properties to be used in biological systems. Bioorganic and Medicinal Chemistry, 2010, 18, 795-802.	1.4	25
35	The first enantioselective synthesis of palinurin. Chemical Communications, 2009, , 3252.	2.2	24
36	The amyloid fold of Gad m 1 epitopes governs IgE binding. Scientific Reports, 2016, 6, 32801.	1.6	21

#	Article	IF	Citations
37	Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2008, 16, 6193-6206.	1.4	20
38	Arylimino-1,2,4-thiadiazolidinones: A new family of potassium channel openers. Bioorganic and Medicinal Chemistry, 1997, 5, 1275-1283.	1.4	19
39	Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors. Archiv Der Pharmazie, 2005, 338, 18-23.	2.1	17
40	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease modifying agents. Expert Opinion on Therapeutic Patents, 2003, 13, 1725-1732.	2.4	15
41	Dioxides of bicyclic thiadiazines: a new family of smooth muscle relaxants. Bioorganic and Medicinal Chemistry, 1995, 3, 179-185.	1.4	14
42	Tautomerism of benzo- and cyclopenta-[1,2,6]thiadiazine S,S-dioxides. Journal of the Chemical Society Perkin Transactions II, 1994, , 1561-1564.	0.9	13
43	On the tautomerism of 2,1,3-benzothiadiazinone S,S-dioxide and related compounds. Tetrahedron, 1999, 55, 12405-12410.	1.0	12
44	Intramolecular oxidative cyclizations in heteroarylthioureas: A versatile pathway to bridgehead heterocyclic systems. Journal of Heterocyclic Chemistry, 1999, 36, 991-995.	1.4	12
45	Hindered Inversion/Rotation in Diheteroaryl Alkyl Amines with a N-(1-Pyrazolyl) Group: Dynamic NMR and Molecular Modelling Studies. Tetrahedron, 2000, 56, 1739-1743.	1.0	12
46	Synthesis and muscarinic activities of O-[(Benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone. Bioorganic and Medicinal Chemistry, 2003, 11, 2263-2268.	1.4	12
47	Lipase-catalysed synthesis of new acetylcholinesterase inhibitors: N -benzylpiperidine aminoacid derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 731-738.	1.4	11
48	Benzothiadiazine Dioxide Human Cytomegalovirus Inhibitors: Synthesis and Antiviral Evaluation of Main Heterocycle Modified Derivatives. Antiviral Chemistry and Chemotherapy, 2003, 14, 107-114.	0.3	11
49	Chlorophenylmethyl benzothiadiazine dioxides derivatives: Potent human cytomegalovirus inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3133-3136.	1.0	10
50	New Synthetic Route to of 1,2,4-Thiadiazolines and 1,3-Thiazolines via Thiadiazolopyridinium Salts. Heterocycles, 1996, 43, 2657.	0.4	10
51	Novel agents for the treatment of human cytomegalovirus infection. Expert Opinion on Therapeutic Patents, 2000, 10, 165-177.	2.4	7
52	Regioselective Lipase-Catalysed Amidation of DicarboxylicN-Blocked Amino Acid Diesters â€“ Effect of the Side-Chain Length. European Journal of Organic Chemistry, 1999, 1999, 2835-2839.	1.2	6
53	Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 2001, 12, 347-351.	0.3	6
54	Synthesis and nematocide activity of S-glycopyranosyl-6,7-diarylthiolumazines. Bioorganic and Medicinal Chemistry, 2004, 12, 4431-4437.	1.4	6

#	Article	IF	Citations
55	Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1919-1921.	1.0	6
56	Bioactive prenylated phenyl derivatives derived from marine natural products: novel scaffolds for the design of BACE inhibitors. MedChemComm, 2014, 5, 474-488.	3.5	6
57	Thiadiazolopyridinium Salts: Intermediates for Heterocyclic Synthesis. Heterocycles, 1994, 38, 1737.	0.4	6
58	Synthesis of nonsymmetrically 3,4â€disubstituted 1,2,5â€thiadiazole dioxides. Journal of Heterocyclic Chemistry, 1998, 35, 297-300.	1.4	5
59	Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activityâ˜†. Bioorganic and Medicinal Chemistry, 2003, 11, 2395-2402.	1.4	5
60	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. Expert Opinion on Therapeutic Patents, 2003, 13, 1725-1732.	2.4	5
61	Base promoted transformation on thiadiazolopyridinium chlorides. Journal of Heterocyclic Chemistry, 1997, 34, 337-340.	1.4	4
62	Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors. , 0, , 307-331.		4
63	Comparative Molecular Field Analysis (CoMFA) on [6] + [6] Fused Pyrazines with Nematocide Properties. QSAR and Combinatorial Science, 1997, 16, 372-376.	1.4	3
64	Reductive Cleavage of Potential Cholinomimetics Thiadiazolidinones: A New Family of Spiro Compounds. European Journal of Organic Chemistry, 2000, 2000, 675-680.	1.2	3
65	Kinase activators as a novel class of antidiabetic agents. Drug Discovery Today, 2012, 17, 528-529.	3.2	3
66	The use of molecular similarity indices in the determination of a bioactive conformation. European Journal of Medicinal Chemistry, 1998, 33, 617-623.	2.6	2
67	Studies on the reactivity of some Nâ€arylâ€•and Nâ€heteroarylâ€N'â€alkylthioureas towards electrophilic reagents. Synthesis of new Nâ€pyridylthioureas and thiazolines marÃa. Journal of Heterocyclic Chemistry, 2001, 38, 435-441.	1.4	2
68	TDZD's: Selective and ATP Noncompetitive Glycogen Synthase Kinase 3 Inhibitors. , 0, , 257-280.		2
69	The Tautomerism of 5â€Aminoâ€3â€oxoâ€1,2,4â€thiadiazole: An Experimental and Theoretical Study. European Journal of Organic Chemistry, 2007, 2007, 5603-5608.	1.2	2
70	The Crystal Structures of Glycogen Synthase Kinase 3. , 0, , 61-82.		1
71	Combined use of pharmacophoric models together with drug metabolism and genotoxicity â€œin silicoâ€• studies in the hit finding process. Journal of Computer-Aided Molecular Design, 2013, 27, 79-90.	1.3	1
72	Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors.. ChemInform, 2005, 36, no.	0.1	0

#	Article	IF	Citations
73	Cyclic Nucleotide Phosphodiesterases and Their Role in Immunomodulatory Responses: Advances in the Development of Specific Phosphodiesterase Inhibitors. ChemInform, 2005, 36, no.	0.1	0
74	GSK-3, a Key Player in Alzheimer's Disease. , 0, , 105-124.		0
75	Protein Kinase Assays for Drug Discovery. , 0, , 189-201.		0